Compare BLKB & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLKB | VCEL |
|---|---|---|
| Founded | 1981 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 2004 | 1996 |
| Metric | BLKB | VCEL |
|---|---|---|
| Price | $37.61 | $33.27 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $50.00 | ★ $57.75 |
| AVG Volume (30 Days) | ★ 546.8K | 508.0K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 142.32 | 60.00 |
| EPS | ★ 0.67 | N/A |
| Revenue | N/A | ★ $276,259,000.00 |
| Revenue This Year | $6.26 | $19.40 |
| Revenue Next Year | $4.25 | $18.24 |
| P/E Ratio | ★ $56.40 | $110.80 |
| Revenue Growth | N/A | ★ 16.45 |
| 52 Week Low | $33.95 | $28.95 |
| 52 Week High | $74.86 | $45.97 |
| Indicator | BLKB | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 47.18 | 44.39 |
| Support Level | $34.65 | $30.12 |
| Resistance Level | $40.38 | $34.77 |
| Average True Range (ATR) | 2.21 | 2.16 |
| MACD | 0.22 | -0.11 |
| Stochastic Oscillator | 54.87 | 16.35 |
Founded in 1981, Blackbaud provides software solutions designed to serve the "social good" community, including nonprofits, foundations, corporations, educational institutions, healthcare institutions, and individual change agents. Through M&A and organic product development efforts, the company has also moved into related areas outside core fundraising, notably into K-12 schools. The firm enables more than $100 billion in donations annually across a customer base in excess of 40,000 customers in over 100 countries.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.